Sign In
Buy HOOK
$1.15
+0 (+0%)
At Close: Jun 03, 2026
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
07:30am, Tuesday, 24'th Sep 2024
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being h
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
11:00am, Monday, 02'nd Sep 2024
The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
HOOKIPA Pharma Announces Board of Directors Changes
08:00am, Friday, 30'th Aug 2024
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its prop
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
08:57am, Wednesday, 28'th Aug 2024
NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprie
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
04:30pm, Thursday, 08'th Aug 2024
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
10:55am, Wednesday, 07'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 634.4% in HOOKIPA Pharma (HOOK). While the effectiveness of this highly sought-after metric is questionable, th
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
11:06am, Thursday, 01'st Aug 2024
HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
08:30am, Monday, 22'nd Jul 2024
NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its prop
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
07:01am, Monday, 08'th Jul 2024
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus pla
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
04:31pm, Monday, 01'st Jul 2024
NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
01:00pm, Tuesday, 04'th Jun 2024
NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platf
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
04:30pm, Thursday, 30'th May 2024
NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenav
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
05:01pm, Thursday, 23'rd May 2024
NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
02:27pm, Thursday, 16'th May 2024
Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential.
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:01am, Thursday, 09'th May 2024
NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo
